Literature DB >> 30713481

Highlight report: General determinants of steatosis.

Wiebke Albrecht1.   

Abstract

Entities:  

Year:  2018        PMID: 30713481      PMCID: PMC6341447          DOI: 10.17179/excli2018-2011

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


× No keyword cloud information.



Recently Christian Hudert and colleagues from the Charité in Berlin published a study about genetic determinants in pediatric non-alcoholic liver disease (Hudert et al., 2018[9]). Non-alcoholic fatty liver disease (NAFLD), the most frequent chronic liver disease in children, is known to be strongly influenced by genetic factors (Nobili et al., 2016[14]; Schwimmer et al., 2006[17]; Makkonen et al., 2009[12]; Anstee et al., 2016[2]). However, genetic determinants of a portal/zone-1 pattern of steatosis in children are not yet known. This would be important, because a portal/zone-1 pattern of steatosis leads to an increased risk of disease progression to fibrosis (Africa et al., 2018[1]; Mann et al., 2016[13]). To address this question, the authors established the Berlin adolescence NAFLD cohort (BaNA) and studied a set of single nucleotide polymorphisms. Interestingly, a variant of the retinyl-palmitate lipase PNPLA3 (rs738409) was associated with a periportal pattern of steatosis and also with an increased risk of progression to fibrosis (Hudert et al., 2018[9]). Therefore, obese children with the PNPLA3 variant may be candidates for a more intensive clinical follow-up and intervention. Due to the current increase in the incidence of liver diseases a better understanding of their pathophysiology is of major importance (Jansen et al., 2017[11]; Vartak et al., 2016[20]; Hammad et al., 2014[7]; Hassan, 2016[8]; Stöber, 2016[18]; Bolt, 2017[3]; Ekhlasi et al., 2017[5]). For this purpose systems modeling as well as the analysis of expression patterns in relation to a phenotype represent frequently applied tools (Godoy et al., 2016[6]; Crespo Yanguas et al., 2016[4]; Jain et al., 2016[10]; Saleem et al., 2016[15]; Schenk et al., 2017[16]; Thiel et al., 2015[19]). The newly established BaNA cohort of adolescent NAFLD with its careful phenotyping and availability of proteome data is an important milestone for a better understanding of disease progression in steatosis.
  20 in total

1.  Prevalence of fatty liver in children and adolescents.

Authors:  Jeffrey B Schwimmer; Reena Deutsch; Tanaz Kahen; Joel E Lavine; Christina Stanley; Cynthia Behling
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

2.  A systematic evaluation of the use of physiologically based pharmacokinetic modeling for cross-species extrapolation.

Authors:  Christoph Thiel; Sebastian Schneckener; Markus Krauss; Ahmed Ghallab; Ute Hofmann; Tobias Kanacher; Sebastian Zellmer; Rolf Gebhardt; Jan G Hengstler; Lars Kuepfer
Journal:  J Pharm Sci       Date:  2014-11-12       Impact factor: 3.534

Review 3.  Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease.

Authors:  Quentin M Anstee; Devanshi Seth; Christopher P Day
Journal:  Gastroenterology       Date:  2016-02-10       Impact factor: 22.682

4.  Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease.

Authors:  Jake P Mann; Rita De Vito; Antonella Mosca; Anna Alisi; Matthew J Armstrong; Massimiliano Raponi; Ulrich Baumann; Valerio Nobili
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

Review 5.  Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Valerio Nobili; Anna Alisi; Kimberly P Newton; Jeffrey B Schwimmer
Journal:  Gastroenterology       Date:  2016-03-19       Impact factor: 22.682

6.  Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: a study in monozygotic and dizygotic twins.

Authors:  Janne Makkonen; Kirsi H Pietiläinen; Aila Rissanen; Jaakko Kaprio; Hannele Yki-Järvinen
Journal:  J Hepatol       Date:  2009-02-18       Impact factor: 25.083

7.  Protocols for staining of bile canalicular and sinusoidal networks of human, mouse and pig livers, three-dimensional reconstruction and quantification of tissue microarchitecture by image processing and analysis.

Authors:  Seddik Hammad; Stefan Hoehme; Adrian Friebel; Iris von Recklinghausen; Amnah Othman; Brigitte Begher-Tibbe; Raymond Reif; Patricio Godoy; Tim Johann; Amruta Vartak; Klaus Golka; Petru O Bucur; Eric Vibert; Rosemarie Marchan; Bruno Christ; Steven Dooley; Christoph Meyer; Iryna Ilkavets; Uta Dahmen; Olaf Dirsch; Jan Böttger; Rolf Gebhardt; Dirk Drasdo; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2014-04-19       Impact factor: 5.153

8.  Gene network activity in cultivated primary hepatocytes is highly similar to diseased mammalian liver tissue.

Authors:  Patricio Godoy; Agata Widera; Wolfgang Schmidt-Heck; Gisela Campos; Christoph Meyer; Cristina Cadenas; Raymond Reif; Regina Stöber; Seddik Hammad; Larissa Pütter; Kathrin Gianmoena; Rosemarie Marchan; Ahmed Ghallab; Karolina Edlund; Andreas Nüssler; Wolfgang E Thasler; Georg Damm; Daniel Seehofer; Thomas S Weiss; Olaf Dirsch; Uta Dahmen; Rolf Gebhardt; Umesh Chaudhari; Kesavan Meganathan; Agapios Sachinidis; Jens Kelm; Ute Hofmann; René P Zahedi; Reinhard Guthke; Nils Blüthgen; Steven Dooley; Jan G Hengstler
Journal:  Arch Toxicol       Date:  2016-06-23       Impact factor: 5.153

9.  Cholestasis-induced adaptive remodeling of interlobular bile ducts.

Authors:  Nachiket Vartak; Amruta Damle-Vartak; Beate Richter; Olaf Dirsch; Uta Dahmen; Seddik Hammad; Jan G Hengstler
Journal:  Hepatology       Date:  2016-01-14       Impact factor: 17.425

Review 10.  Connexins and pannexins in liver damage.

Authors:  Sara Crespo Yanguas; Joost Willebrords; Michaël Maes; Tereza Cristina da Silva; Isabel Veloso Alves Pereira; Bruno Cogliati; Maria Lucia Zaidan Dagli; Mathieu Vinken
Journal:  EXCLI J       Date:  2016-02-25       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.